공시 • Feb 04
Inotiv, Inc. to Report Q1, 2026 Results on Feb 09, 2026 Inotiv, Inc. announced that they will report Q1, 2026 results Pre-Market on Feb 09, 2026 공시 • Jan 08
Inotiv, Inc. Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing Rule On December 31, 2025, Inotiv, Inc. received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notification Letter has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. The Notification Letter provides an initial 180 calendar day period, or until June 29, 2026, in which to regain compliance, pursuant to Nasdaq Listing Rule 5810(c)(3)(A). Nasdaq will notify the Company that it has achieved compliance with the Minimum Bid Price Rule if at any time before that date the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, unless Nasdaq exercises its discretion to require a longer period. If the Company does not regain compliance by June 29, 2026, the Company may be eligible for an additional 180-day grace period. The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the minimum bid requirement. However, there can be no assurance that the Company will regain compliance with the minimum bid requirement during the 180-day compliance period, secure a second period of 180 days to regain compliance, or maintain compliance with the other Nasdaq listing requirements. 공시 • Nov 21
Inotiv, Inc. to Report Q4, 2025 Results on Dec 03, 2025 Inotiv, Inc. announced that they will report Q4, 2025 results After-Market on Dec 03, 2025 공시 • Nov 18
Inotiv, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended September 30, 2025 Inotiv, Inc. provided revenue guidance for the fourth quarter and full year ended September 30, 2025. For the quarter, The company anticipates revenue between $137.5 million and $138.5 million for Fourth Quarter Fiscal Year 2025.
For the year, The company anticipates revenue between $512.5 million and $513.5 million for Fiscal Year 2025. 공시 • Sep 27
Inotiv, Inc. Enters into a Stipulation and Agreement of Settlement to Settle the Securities Class Action Pending in the United States District Court for the Northern District of Indiana On September 25, 2025, Inotiv, Inc. (the “Company”) entered into a Stipulation and Agreement of Settlement to settle the securities class action pending in the United States District Court for the Northern District of Indiana, captioned In re Inotiv, Inc. Securities Litigation, Case No. 4:22-cv-00045-PPS-JEM (the “Securities Class Action” and the proposed settlement, the “Proposed Securities Settlement”). The Company entered into the Proposed Securities Settlement to eliminate the uncertainty, burden, and expense of protracted litigation. The Proposed Securities Settlement does not assign or reflect any admission of wrongdoing or liability by the Company or the individual defendants, all of whom deny any wrongdoing. The Proposed Securities Settlement is subject in all respects to court approval and there can be no assurance that the court will approve the Proposed Securities Settlement. If approved by the court, the Proposed Securities Settlement will fully resolve the Securities Class Action claims against the Company and the individual defendants Robert Leasure, Jr., Beth Taylor, John Sagartz, and Carmen Wilbourn. As consideration for the Proposed Securities Settlement, the Company will cause to be paid a cash settlement payment of $8,750,000 (“Cash Payment”) to the members of the putative class, which is expected to include all persons and entities who purchased or otherwise acquired shares of the Company’s common stock between September 21, 2021 and May 20, 2022 or who held shares of the Company’s common stock and were entitled to vote on matters necessary to effectuate the Company’s acquisition of Envigo RMS, LLC at a special meeting of the Company’s shareholders on November 4, 2021 (subject to certain exclusions). Plaintiff will seek attorneys’ fees and costs, the amount of which will be determined by the court and funded from the Cash Payment. The Company expects the Cash Payment to be fully funded by available insurance. 공시 • Aug 30
Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.
Security Name: Common Shares
Security Type: Common Stock
Transaction Features: At the Market Offering 공시 • Jul 23
Inotiv, Inc. to Report Q3, 2025 Results on Aug 06, 2025 Inotiv, Inc. announced that they will report Q3, 2025 results After-Market on Aug 06, 2025 공시 • Apr 24
Inotiv, Inc. to Report Q2, 2025 Results on May 07, 2025 Inotiv, Inc. announced that they will report Q2, 2025 results on May 07, 2025 공시 • Jan 24
Inotiv, Inc., Annual General Meeting, Mar 13, 2025 Inotiv, Inc., Annual General Meeting, Mar 13, 2025. Location: courtyard marriott lafayette, 150 fairington avenue, lafayette, in 47905, United States 공시 • Jan 23
Inotiv, Inc. to Report Q1, 2025 Results on Feb 05, 2025 Inotiv, Inc. announced that they will report Q1, 2025 results After-Market on Feb 05, 2025 공시 • Dec 19
Inotiv, Inc. has completed a Follow-on Equity Offering in the amount of $25.5 million. Inotiv, Inc. has completed a Follow-on Equity Offering in the amount of $25.5 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 6,000,000
Price\Range: $4.25
Discount Per Security: $0.2125 공시 • Dec 18
Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.
Security Name: Common Shares
Security Type: Common Stock 공시 • Dec 06
Inotiv, Inc. Auditor Raises 'Going Concern' Doubt Inotiv, Inc. filed its 10-K on Dec 04, 2024 for the period ending Sep 30, 2024. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. 공시 • Nov 21
Inotiv, Inc. to Report Q4, 2024 Results on Dec 03, 2024 Inotiv, Inc. announced that they will report Q4, 2024 results After-Market on Dec 03, 2024 Reported Earnings • Aug 13
Third quarter 2024 earnings released: US$1.00 loss per share (vs US$0.072 profit in 3Q 2023) Third quarter 2024 results: US$1.00 loss per share (down from US$0.072 profit in 3Q 2023). Revenue: US$105.8m (down 33% from 3Q 2023). Net loss: US$26.1m (down US$27.9m from profit in 3Q 2023). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings. 공시 • Aug 11
Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Inotiv, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.
Security Name: Common Shares
Security Type: Common Stock
Transaction Features: At the Market Offering 공시 • Jul 25
Inotiv, Inc. to Report Q3, 2024 Results on Aug 08, 2024 Inotiv, Inc. announced that they will report Q3, 2024 results After-Market on Aug 08, 2024 공시 • May 17
Inotiv, Inc. Withdraws Financial Guidance for Fiscal Year 2024 Inotiv, Inc. announced that due to the significant impact that NHP revenue has on consolidated revenue and margins, and the current uncertainty in customer demand for NHPs, the company is withdrawing financial guidance for fiscal year 2024. 공시 • May 15
Inotiv, Inc. announced delayed 10-Q filing On 05/13/2024, Inotiv, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • May 01
Inotiv, Inc. to Report Q2, 2024 Results on May 10, 2024 Inotiv, Inc. announced that they will report Q2, 2024 results Pre-Market on May 10, 2024 공시 • Feb 09
An unknown buyer acquired RMS facilities in Spain and France from Inotiv, Inc. (NasdaqCM:NOTV). An unknown buyer acquired RMS facilities in Spain and France from Inotiv, Inc. (NasdaqCM:NOTV) During the three months ended December 31, 2023.An unknown buyer completed the acquisition of RMS facilities in Spain and France from Inotiv, Inc. (NasdaqCM:NOTV) During the three months ended December 31, 2023. 공시 • Feb 08
Inotiv, Inc. Reaffirms Earnings Guidance for the Fiscal 2024 Inotiv, Inc. reaffirmed earnings guidance for the fiscal 2024. For the fiscal, the company expects revenues to be in the range of $580 million to $590 million. Reported Earnings • Feb 08
First quarter 2024 earnings released: US$0.60 loss per share (vs US$3.41 loss in 1Q 2023) First quarter 2024 results: US$0.60 loss per share (improved from US$3.41 loss in 1Q 2023). Revenue: US$135.5m (up 10% from 1Q 2023). Net loss: US$15.4m (loss narrowed 82% from 1Q 2023). Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings. 공시 • Jan 30
Inotiv, Inc. to Report Q1, 2024 Results on Feb 07, 2024 Inotiv, Inc. announced that they will report Q1, 2024 results After-Market on Feb 07, 2024 공시 • Jan 27
Inotiv, Inc., Annual General Meeting, Mar 14, 2024 Inotiv, Inc., Annual General Meeting, Mar 14, 2024, at 10:00 US Eastern Standard Time. Location: the Courtyard Marriott Lafayette, 150 Fairington Avenue Lafayette Indiana United States Agenda: To elect three directors to serve until the 2027 annual meeting of shareholders; to ratify the appointment of ernst & young llp as the company’s independent registered public accounting firm for fiscal 2024; and to approve the inotiv, inc. 2024 equity incentive plan. Recent Insider Transactions • Dec 18
Chief Operating Officer recently bought €136k worth of stock On the 14th of December, John Beattie bought around 48k shares on-market at roughly €2.84 per share. This transaction amounted to 85% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of €169k worth in shares. Reported Earnings • Dec 13
Full year 2023 earnings released: US$4.10 loss per share (vs US$13.84 loss in FY 2022) Full year 2023 results: US$4.10 loss per share (improved from US$13.84 loss in FY 2022). Revenue: US$572.4m (up 4.5% from FY 2022). Net loss: US$105.1m (loss narrowed 69% from FY 2022). Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance. 공시 • Dec 12
Inotiv, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Inotiv, Inc. provided earnings guidance for the fiscal year 2024. For the year, the company revenues are expected to be in the range of $580 million to $590 million. 공시 • Nov 28
Inotiv, Inc. to Report Q4, 2023 Results on Dec 11, 2023 Inotiv, Inc. announced that they will report Q4, 2023 results After-Market on Dec 11, 2023 공시 • Oct 17
Inotiv, Inc. Announces Changes to Its Board Composition Inotiv, Inc. announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Boards succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board. Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial stage biotech company. Previously, Ms. Coelho was Executive Vice President, CFO and Chief Business Development Officer of CinCor Pharma, Inc., where she led the $190 million IPO in January 2022, followed by a follow-on offering, prior to its sale to AstraZeneca for approximately $1.8 billion. Her previous experience includes serving as CFO of BioDelivery Sciences International, Balchem Corporation and Diversey, the finance lead for Novartis oncology hematology franchise and Global Head of Oncology Development Finance at Novartis, as well as various positions of increasing responsibility within Mars, Inc. Ms. Coelho is a member of the boards of directors of First Wave Biopharma, Inc. and HOOKIPA Pharma Inc. 공시 • Aug 30
Harlan Holdings Ltd. acquired Israeli Businesses from Inotiv, Inc. for $3.7 million. Harlan Holdings Ltd. acquired Israeli Businesses from Inotiv, Inc. for $3.7 million on August 29, 2023.
Harlan Holdings Ltd. completed the acquisition Israeli Businesses from Inotiv, Inc. on August 29, 2023. New Risk • Aug 16
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €89.8m (US$98.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$48m net loss next year). Market cap is less than US$100m (€89.8m market cap, or US$98.0m). 공시 • Aug 11
Inotiv, Inc. Revises Earnings Guidance for the Full Year 2023 Inotiv, Inc. revised earnings guidance for the full year 2023. For the year, the company expects revenue to at least $570 million in revenue, which is down from $580 million in previous guidance. Reported Earnings • Aug 11
Third quarter 2023 earnings released: EPS: US$0.072 (vs US$0.15 loss in 3Q 2022) Third quarter 2023 results: EPS: US$0.072 (up from US$0.15 loss in 3Q 2022). Revenue: US$157.5m (down 8.8% from 3Q 2022). Net income: US$1.84m (up US$5.57m from 3Q 2022). Profit margin: 1.2% (up from net loss in 3Q 2022). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance. 공시 • Jul 25
Inotiv, Inc. to Report Q3, 2023 Results on Aug 10, 2023 Inotiv, Inc. announced that they will report Q3, 2023 results After-Market on Aug 10, 2023 Reported Earnings • May 12
Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.24 loss in 2Q 2022) Second quarter 2023 results: US$0.39 loss per share (further deteriorated from US$0.24 loss in 2Q 2022). Revenue: US$151.5m (up 7.9% from 2Q 2022). Net loss: US$9.99m (loss widened 64% from 2Q 2022). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 131 percentage points per year, which is a significant difference in performance. 공시 • May 12
Inotiv, Inc. Confirms Revenue Guidance for the Fiscal Year 2023 Inotiv, Inc. confirmed revenue guidance for the fiscal year 2023. For the period, the company confirmed guidance of at least $580 million of revenue. 공시 • Feb 15
Inotiv, Inc. Reiterates Financial Guidance for the Fiscal Year Ending September 30, 2023 Inotiv, Inc. reiterated financial guidance for the fiscal year ending September 30, 2023. For the year, the company confirmed the guidance of at least $580 million of revenue. 공시 • Feb 14
Inotiv, Inc. Reports Goodwill Impairment Charges for the First Quarter Ended December 31, 2022 Inotiv, Inc. reported goodwill impairment charges for the first quarter ended December 31, 2022. For the quarter, the company reported goodwill impairment loss of $66,367,000. 공시 • Feb 07
Inotiv, Inc. to Report Q1, 2023 Results on Feb 13, 2023 Inotiv, Inc. announced that they will report Q1, 2023 results After-Market on Feb 13, 2023 공시 • Jan 28
Inotiv, Inc., Annual General Meeting, Mar 16, 2023 Inotiv, Inc., Annual General Meeting, Mar 16, 2023, at 10:00 US Eastern Standard Time. Location: Courtyard Marriott Lafayette 150 Fairington Avenue Lafayette Indiana United States Agenda: To elect two directors to serve until the 2026 Annual Meeting of Shareholders; and to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2023. 공시 • Jan 12
Inotiv, Inc. Provides Revenue Guidance for the First Quarter and Second Quarter to Fourth Quarter and Earnings Guidance for the Full Year Fiscal 2023 Inotiv, Inc. provided revenue guidance for the first quarter and second quarter to Fourth Quarter and earnings guidance for the Full Year Fiscal 2023. For the first quarter, the company's revenue expected to be $118 million to $122 million. For second quarter to Fourth Quarter of 2023, the company estimated revenue of approximately $460 million.For Fiscal Year 2023, company expects revenue of at least $580 million. 공시 • Jan 05
Inotiv, Inc. to Report Q4, 2022 Results on Jan 10, 2023 Inotiv, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Jan 10, 2023 공시 • Dec 16
Inotiv, Inc. announced delayed annual 10-K filing On 12/15/2022, Inotiv, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Dec 13
Inotiv, Inc. Provides Revenue Guidance for the Fiscal Year 2022 Inotiv, Inc. provided revenue guidance for the fiscal year 2022. Total revenue for fiscal year 2022 is expected to increase to approximately $547.7 million from total revenue of $89.6 million in fiscal year 2021. 공시 • Nov 30
Inotiv, Inc. Announces Additional Site Consolidation Plan in the U.S Inotiv, Inc. announced plans to close two isolator facilities in Indianapolis, Indiana, and consolidate them with existing facilities in the U.S. The Company’s subsidiaries in France and the U.K. have also proposed a consolidation plan of two facilities in Gannat, France, and Blackthorn, Bicester U.K., into existing facilities. The Company also provided an update on its previously announced site optimization plans in Virginia, Michigan, and Pennsylvania. 공시 • Nov 29
Inotiv, Inc. to Report Q4, 2022 Results on Dec 12, 2022 Inotiv, Inc. announced that they will report Q4, 2022 results on Dec 12, 2022 공시 • Aug 18
Bronstein, Gewirtz & Grossman, LLC Notifies Investors That A Class Action Lawsuit Has Been Filed Against Inotiv, Inc Bronstein, Gewirtz & Grossman, LLC notified investors that a class action lawsuit has been filed against Inotiv, Inc. (Inotiv or the Company) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Inotiv securities between September 21, 2021 and June 13, 2022, inclusive (the Class Period). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws. The Complaint alleges the Defendants made false and/or misleading statements that misrepresented and failed to disclose the following adverse facts pertaining to the Company's business, operations, and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: Envigo and the Company's Cumberland, Virginia facility (the Cumberland Facility) engaged in widespread and flagrant violations of the Animal Welfare Act of 1966 (AWA); Envigo and the Company's Cumberland Facility continuously violated the AWA; Envigo and the Company did not properly remedy issues with regards to animal welfare at the Cumberland Facility; as a result, the Company was likely to face increased scrutiny and governmental action; Inotiv would imminently shut down two facilities, including the Cumberland Facility; the Company did not engage in proper due diligence; and as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. 공시 • Aug 11
Inotiv, Inc. Revises Earnings Guidance for the Fiscal Year Ending September 30, 2022 Inotiv, Inc. revised earnings guidance for the fiscal year ending September 30, 2022. For the fiscal year 2022, based on current conditions and outlook, the company has updated its annual guidance as forecasted annual revenue of at least $550 million, up from prior annual revenue guidance of at least $510 million. 공시 • Aug 04
Law Offices of Howard G. Smith Files Lawsuit Against Inotiv, Inc Offices of Howard G. Smith announces that investors with substantial losses have the opportunity to lead the securities fraud class action lawsuit against Inotiv, Inc. The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) Envigo and Inotiv's Cumberland, Virginia facility (the "Cumberland Facility") engaged in widespread and flagrant violations of the AWA; (2) Envigo and Inotiv's Cumberland Facility continuously violated the AWA; (3) Envigo and Inotiv did not properly remedy issues with regards to animal welfare at the Cumberland Facility; (4) as a result, Inotiv was likely to face increased scrutiny and governmental action; (5) Inotiv would imminently shut down two facilities, including the Cumberland Facility; (6) Inotiv did not engage in proper due diligence; and (7) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. 공시 • Aug 02
Inotiv, Inc. to Report Q3, 2022 Results on Aug 10, 2022 Inotiv, Inc. announced that they will report Q3, 2022 results After-Market on Aug 10, 2022 공시 • Jul 27
Inotiv, Inc. Decides to Close Two of its Facilities, a Purpose-Bred Canine Facility in Cumberland, Virginia On June 13, 2022, Inotiv, Inc. (the ‘Company’) filed a Current Report on Form 8-K (the ‘Original Form 8-K’) disclosing that the Company had decided to close two of its facilities, a purpose-bred canine facility in Cumberland, Virginia and a rodent breeding facility in Dublin, Virginia (the ‘sites’), both of which were acquired by the Company in connection with its acquisition of Envigo RMS Holding Corp. (‘Envigo’) in November 2021. The decision to close the Cumberland facility was due to the fact that the required investments and lead time to improve the facility have recently increased. Further, as disclosed by the Company on July 18, 2022, Envigo has entered into a settlement with the U.S. Department of Justice (‘DOJ’) and the U.S. Department of Agriculture (‘USDA’) that resolves an extensive civil and administrative investigation into the Cumberland facility and incorporates a transfer plan related to the transfer of the canines out of the facility. The Company intends to implement an orderly closure plan for the Cumberland facility, and the Company expects the Cumberland facility exit to be complete by October 2022. Any potential decision to sell the facility and related property may extend past that date. The closure of the Dublin facility is part of the Company’s ongoing restructuring and site optimization plan. The Company intends to relocate the current production at the Dublin facility to other facilities that have recently been expanded or refurbished. The Company expects the Dublin facility transition to be complete by December 2022. 공시 • Jul 08
Inotiv, Inc. (NasdaqCM:NOTV) acquired Protypia, Inc. for $11 million. Inotiv, Inc. (NasdaqCM:NOTV) acquired Protypia, Inc. for $11 million on July 7, 2022. Transaction consideration totaled approximately $11 million, consisting of approximately $9.5 million in cash, Inotiv common shares having a value of approximately $0.9 million, and $0.6 million in unsecured subordinated promissory notes. The company expects to retain all existing Protypia employees and maintain the operations in Nashville, TN.
Inotiv, Inc. (NasdaqCM:NOTV) completed the acquisition of Protypia, Inc. on July 7, 2022. 공시 • Jun 26
Inotiv, Inc. Announces Retirement of James Harkness as Chief Operating Officer, Effective from September 30, 2022 Inotiv, Inc. announced that James Harkness, the Company’s Chief Operating Officer, Research Models & Services, will be retiring from the Company, effective on September 30, 2022. 공시 • Jun 25
Kirby McInerney LLP Announces Filing of Securities Class Action on Behalf of Inotiv, Inc. Investors Kirby McInerney LLP announced that a class action lawsuit has been filed in the U.S. District Court for the Northern District of Indiana on behalf of those who acquired Inotiv, Inc. (“Inotiv”) securities from September 21, 2021 through June 13, 2022, both dates inclusive (the “Class Period”). Investors have until August 22, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit. The lawsuit alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Envigo and Inotiv’s Cumberland Facility engaged in widespread and flagrant violations of the AWA; (2) Envigo and Inotiv’s Cumberland Facility continuously violated the AWA; (3) Envigo and Inotiv did not properly remedy issues with regards to animal welfare at the Cumberland Facility; (4) as a result, Inotiv was likely to face increased scrutiny and governmental action; (5) Inotiv would imminently shut down two facilities, including the Cumberland Facility; (6) Inotiv did not engage in proper due diligence; and (7) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. 공시 • Jun 23
Inotiv, Inc. Appoints Glenn Washer as Group President, Safety Assessment Inotiv, Inc. announced that Glenn Washer joined the Company as Group President, Safety Assessment, effective June 20, 2022. Washer is a board-certified toxicologist with over thirty-five years of experience in the CRO/biopharma industry, most recently serving as President of Frontage Laboratories, North America, where he led the support groups serving all business units, and as Executive Vice President for Global Safety and Toxicology Services, responsible for several sites in the U.S. and China. Prior to his tenure at Frontage, Washer served as Corporate Senior Vice President, responsible for Charles River Laboratories’ North America Safety Assessment business. Washer’s key responsibilities will include: Leading the growth and development of the Company’s safety assessment business unit; Developing and refining the Company’s business processes and operating model to be an integrated, efficient, and dynamic safety assessment business unit; and Advancing and implementing plans to consistently deliver excellent client experiences across the company's safety assessment sites. Reported Earnings • May 15
Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.065 loss in 2Q 2021) Second quarter 2022 results: US$0.24 loss per share (down from US$0.065 loss in 2Q 2021). Revenue: US$140.3m (up US$121.6m from 2Q 2021). Net loss: US$6.09m (loss widened US$5.36m from 2Q 2021). Over the next year, revenue is forecast to grow 102%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 198 percentage points per year, which is a significant difference in performance. 공시 • May 14
Inotiv, Inc. Provides Earnings Guidance for the Second Half and Full Fiscal Year 2022 Inotiv, Inc. provided earnings guidance for the second half and full fiscal year 2022. For the period, the company expected revenue of $290 million in second half of fiscal year 2022 for a total fiscal 2022 annual revenue of at least $510 million, implying year over year internal growth of 30% or more. 공시 • Apr 26
Inotiv, Inc. (NasdaqCM:NOTV) acquired Histion, LLC on April 25, 2022. Inotiv, Inc. (NasdaqCM:NOTV) acquired Histion, LLC on April 25, 2022.
Inotiv, Inc. (NasdaqCM:NOTV) completed the acquisition of Histion, LLC on April 25, 2022. 공시 • Feb 16
Inotiv, Inc. announced delayed 10-Q filing On 02/15/2022, Inotiv, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Reported Earnings • Feb 11
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat First quarter 2022 results: US$3.93 loss per share (down from US$0.033 loss in 1Q 2021). Revenue: US$84.2m (up 371% from 1Q 2021). Net loss: US$83.0m (loss widened US$82.7m from 1Q 2021). Revenue exceeded analyst estimates by 16%. Over the next year, revenue is forecast to grow 206%, compared to a 44% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 295 percentage points per year, which is a significant difference in performance. 공시 • Feb 04
Inotiv, Inc., Annual General Meeting, Mar 17, 2022 Inotiv, Inc., Annual General Meeting, Mar 17, 2022, at 10:00 Eastern Standard Time. Location: Courtyard Marriott Lafayette 150 Fairington Avenue Lafayette Indiana United States Agenda: To elect two directors to serve until the 2025 annual meeting of shareholders; to ratify the appointment of ernst & young us llp as the company’s independent registered public accounting firm for fiscal 2022; and to approve an amendment to our amended and restated 2018 equity incentive plan. Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €23.40, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 47x in the Life Sciences industry in Europe. Total returns to shareholders of 1,883% over the past three years. 공시 • Jan 12
Inotiv, Inc. (NasdaqCM:NOTV) acquired Integrated Laboratory Systems, Inc. from Sier Capital for $52.8 million. Inotiv, Inc. (NasdaqCM:NOTV) acquired Integrated Laboratory Systems, Inc. from Sier Capital for $52.8 million on January 10, 2022.The purchase price consist of $38 million in cash and 429,118 Inotiv common shares having a value of $18 million based on the volume weighted average closing price of Inotiv shares as reported by NASDAQ for the 20 trading-day period ending on January 6, 2022. In 2021, Integrated Laboratory Systems generated revenue of approximately $20 million. Inotiv expects to retain all existing ILS employees. Edgemont Partners served as the exclusive financial advisor for Sier Capital and ILS in connection with the transaction.
Inotiv, Inc. (NasdaqCM:NOTV) completed the acquisition of Integrated Laboratory Systems, Inc. from Sier Capital on January 10, 2022. Valuation Update With 7 Day Price Move • Jan 10
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €30.60, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 58x in the Life Sciences industry in Europe. Total returns to shareholders of 2,682% over the past three years. 공시 • Jan 07
Inotiv, Inc. (NasdaqCM:NOTV) acquired Rabbit Breeding and Supply Business of Robinson Services Inc. Inotiv, Inc. (NasdaqCM:NOTV) acquired Rabbit Breeding and Supply Business of Robinson Services Inc. on January 6, 2022. Inotiv plans to consolidate the RSI business into existing Inotiv facilities during 2022.
Inotiv, Inc. (NasdaqCM:NOTV) completed the acquisition of Rabbit Breeding and Supply Business of Robinson Services Inc. on January 6, 2022. Reported Earnings • Dec 17
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: US$0.83 (up from US$0.43 loss in FY 2020). Revenue: US$89.6m (up 48% from FY 2020). Net income: US$10.9m (up US$15.6m from FY 2020). Profit margin: 12% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 8.5%. Over the next year, revenue is forecast to grow 373%, compared to a 30% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 236% per year, which means it is tracking significantly ahead of earnings growth. 공시 • Dec 15
Inotiv, Inc. Announces the Launch of New Genetically Engineered Rodent Models for Sars-Cov-2 Research Inotiv, Inc. announced that its Research Models and Services business, consisting of recently-acquired Envigo, has launched novel transgenic rodent models designed specifically for SARS-CoV-2 (COVID-19) and Coronavirus research. Three new models are now available: Mouse model with the human ACE2 gene targeted to the mouse ACE2 locus Rat model with the human ACE2 gene targeted to the rat ACE2 locus Mouse model with human ACE2 and TMPRSS2 genes targeted to the mouse loci Standard laboratory rodent models do not contain the human genes the SARS-CoV-2 virus use to attach to, enter, and infect human cells. Therefore, they are not useful for the study of vaccines and therapies targeting COVID-19. Creating transgenic rodent models which contain these human genes enables the study of treatments and vaccines in the laboratory. The mouse and rat models developed by Inotiv for the study of SARS-CoV-2 overcome the limitations of other commercially available human ACE2 transgenic rodent models: Inotiv’s models express human ACE2 protein at physiologically relevant levels. The effects produced upon SARS-CoV-2 infection in these models more closely parallel human COVID-19 disease. Inotiv’s models do not contain a functional mouse or rat ACE2 gene. Other commercially available models contain these endogenous genes which may confound experimental results. Inotiv has developed the first commercially available human ACE2 transgenic rat model which will have additional utility for studying the neurological impact of SARS-CoV-2 infection and the toxicology of vaccines and drugs in development. Inotiv utilizes CRISPR/Cas9 for precision gene editing in the production of transgenic rodents. This technology was used to mediate the integration of a codon optimized human ACE2 cDNA expression cassette into the mouse and rat ACE2 gene loci so that the endogenous ACE2 gene promoter drives expression of the human gene while simultaneously eliminating the mouse or rat gene. Therefore, human ACE2 receptors in these models are expressed at normal levels, thus enabling them to mirror the disease pathology seen in humans. Board Change • Nov 14
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Matt Neff was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Sep 23
Forecast to breakeven in 2022 The 2 analysts covering Inotiv expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$10.5m in 2022. Average annual earnings growth of 80% is required to achieve expected profit on schedule. 공시 • Sep 23
Inotiv, Inc. (NasdaqCM:NOTV) entered into a definitive agreement to acquire Envigo RMS, Inc. for approximately $540 million. Inotiv, Inc. (NasdaqCM:NOTV) entered into a definitive agreement to acquire Envigo RMS, Inc. for approximately $540 million on September 21, 2021. The transaction consideration is on a cash-free and debt-free basis and consists of $200 million of cash and 9.4 million Inotiv common shares, subject to certain adjustments at closing. The transaction values Envigo at an enterprise value of approximately $545 million. As reported, $7.5 million of the consideration shall be placed in the Adjustment Escrow Account by Inotiv as a source of payment with respect to a purchase price adjustment and $0.25 million of the consideration shall be deposited with the Securityholder Representative, Shareholder Representative Services LLC for the payment or reimbursement of expenses incurred by the Securityholder Representative in performing its duties pursuant to the transaction agreement. Inotiv has received committed debt financing to fund the cash portion of the transaction. The commitments have been received from a group of lenders and from Jefferies LLC to provide $275 million of secured and unsecured financing to pay the cash portion of the merger consideration and related transaction expenses and to provide Inotiv with additional liquidity following the completion of the acquisition. Upon closing of the transaction, Inotiv shareholders are expected to own approximately 64% and Envigo shareholders are expected to own approximately 36% of the combined company on a fully diluted basis.
For the fiscal year ended December 31, 2020, Envigo reported net loss of $53.5 million and adjusted EBITDA of $24.4 million. At the effective time of the merger, Inotiv’s board of directors will be expanded from five to seven members and will consist of its Chief Executive Officer, its Chief Strategy Officer, two of its existing independent directors, one director designated by each of Jermyn Street Associates LLC and Savanna Holdings LLC (collectively, the "Nominating Holders") and one director nominated by us and approved by the Nominating Holders. After consummation of the merger, if it is consummated, the Nominating Holders and certain other Envigo shareholders, each Nominating Holder will have the right to designate a one member of Envigo’s board and to approve the director who succeeds the mutually approved director (who may be the same mutually approved director) for as long as they continue to hold 5% or more of its outstanding common shares. The combined company, under the leadership of Robert Leasure, Jr. as President and Chief Executive Officer, expects to retain existing executive-level leadership and staff after transaction close. The operational leadership from Inotiv and Envigo will maintain critical roles. The closing of the transaction is subject to customary closing conditions including any applicable waiting periods under the HSR Act relating to the transactions contemplated by the agreement shall have expired or been terminated; approval by stockholders of Envigo; the necessary shareholder matters shall have been duly approved and adopted by Inotiv shareholders by the requisite vote; required regulatory approval; accuracy of representations and warranties set forth in the Merger Agreement, the absence of a material adverse effect (as defined in the Merger Agreement) with respect to either party; Inotiv stock issuable as merger consideration shall have been approved for listing on NASDAQ; the Inotiv voting and support agreements shall be in full force and effect at the closing; delivery of closing deliverables including a duly executed counterpart to the shareholder agreement, a duly executed copy of the Paying Agent agreement; a counterpart of the Escrow agreement and others. The Board of Directors of Envigo approved the agreement and recommends approval of the agreement by the stockholders of Envigo. The Board of Directors of Inotiv, Inc. also approved the agreement. The transaction is expected to close in the fourth calendar quarter of 2021. The transaction is expected to be margin accretive to EBITDA from day 1 driven by vertical integration without considering potential synergies and expected to be immediately earnings accretive to Inotiv earnings and margins (prior to potential synergies) post-close. Jefferies LLC is serving as exclusive financial advisor and Stephen J. Hackman of Ice Miller LLP acted as legal advisor to Inotiv. Jonathan Schaffzin, Kimberly Petillo-Décossard and Ross Sturman of Cahill Gordon & Reindel LLP acted as legal advisors to Envigo. Executive Departure • Sep 15
Chief Commercial Officer Joseph Flynn has left the company On the 8th of September, Joseph Flynn's tenure as Chief Commercial Officer ended after 2.5 years in the role. As of June 2021, Joseph still personally held 128.39k shares (€2.8m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 2.08 years. Reported Earnings • Aug 12
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.081 loss in 3Q 2020) The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$22.9m (up 45% from 3Q 2020). Net loss: US$2.27m (loss widened 158% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 245 percentage points per year, which is a significant difference in performance. 공시 • Aug 04
Inotiv, Inc. (NasdaqCM:NOTV) acquired Gateway Pharmacology Laboratories LLC. Inotiv, Inc. (NasdaqCM:NOTV) acquired Gateway Pharmacology Laboratories LLC on August 2, 2021.
Inotiv, Inc. (NasdaqCM:NOTV) completed the acquisition of Gateway Pharmacology Laboratories LLC on August 2, 2021. 공시 • Jul 16
Inotiv, Inc. (NasdaqCM:NOTV) acquired Physical assets of Novel Therapies for $1.3 million. Inotiv, Inc. (NasdaqCM:NOTV) acquired Physical assets of Novel Therapies for $1.3 million on July 15, 2021.
Inotiv, Inc. (NasdaqCM:NOTV) completed the acquisition of Physical assets of Novel Therapies on July 15, 2021. 공시 • Jul 14
Inotiv, Inc. (NasdaqCM:NOTV) acquired genetic toxicology assets from Sigma-Aldrich Corporation. Inotiv, Inc. (NasdaqCM:NOTV) acquired genetic toxicology assets from Sigma-Aldrich Corporation on July 12, 2021. Under the transaction, Inotiv acquired key genetic toxicology assets from MilliporeSigma's BioReliance® portfolio, including standard operating procedures, stock cultures, historic control data and client list. The transaction consists of a sales-based royalty agreement and does not require upfront funding from Inotiv. Inotiv will also offer employment to certain MilliporeSigma employees. As part of the arrangement, Gopala Krishna, has joined Inotiv as Senior Vice President, Genetic Toxicology, to lead the Company’s genetic toxicology service offering.
Inotiv, Inc. (NasdaqCM:NOTV) completed the acquisition of genetic toxicology assets from Sigma-Aldrich Corporation on July 12, 2021. Recent Insider Transactions • May 18
Chief Operating Officer recently bought €95k worth of stock On the 13th of May, John Beattie bought around 5k shares on-market at roughly €18.98 per share. In the last 3 months, they made an even bigger purchase worth €95k. John has been a buyer over the last 12 months, purchasing a net total of €217k worth in shares. 
